This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ReNeuron Group 미래 성장

Future 기준 확인 0/6

현재 ReNeuron Group 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	37.0%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 ReNeuron Group 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

AIM:RENE - 애널리스트의 미래 추정치 및 과거 재무 데이터 (GBP Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
9/30/2023	0	-5	-5	-5	N/A
6/30/2023	0	-5	-7	-6	N/A
3/31/2023	1	-5	-8	-7	N/A
12/31/2022	1	-7	-8	-7	N/A
9/30/2022	1	-8	-7	-7	N/A
6/30/2022	1	-9	-8	-7	N/A
3/31/2022	0	-10	-8	-7	N/A
12/31/2021	0	-10	-8	-8	N/A
9/30/2021	0	-9	-8	-8	N/A
6/30/2021	0	-10	-7	-7	N/A
3/31/2021	0	-11	-6	-6	N/A
12/31/2020	0	-13	-9	-9	N/A
9/30/2020	0	-15	-11	-11	N/A
6/30/2020	3	-13	-13	-13	N/A
3/31/2020	6	-11	-14	-14	N/A
12/31/2019	6	-12	-12	-12	N/A
9/30/2019	6	-13	-10	-10	N/A
6/30/2019	5	-14	-11	-11	N/A
3/31/2019	3	-14	-12	-12	N/A
12/31/2018	3	-14	-14	-14	N/A
9/30/2018	3	-13	-15	-15	N/A
6/30/2018	2	-16	-15	-15	N/A
3/31/2018	1	-18	-15	-15	N/A
12/31/2017	1	-18	-15	-15	N/A
9/30/2017	1	-17	-15	-14	N/A
6/30/2017	1	-17	N/A	-13	N/A
3/31/2017	1	-16	N/A	-13	N/A
12/31/2016	1	-15	N/A	-12	N/A
9/30/2016	1	-15	N/A	-12	N/A
6/30/2016	1	-13	N/A	-12	N/A
3/31/2016	1	-11	N/A	-12	N/A
12/31/2015	1	-10	N/A	-10	N/A
9/30/2015	1	-9	N/A	-9	N/A
6/30/2015	1	-9	N/A	-8	N/A
3/31/2015	1	-9	N/A	-8	N/A
12/31/2014	1	-8	N/A	-8	N/A
9/30/2014	1	-8	N/A	-7	N/A
6/30/2014	1	-8	N/A	-7	N/A
3/31/2014	1	-7	N/A	-6	N/A
12/31/2013	0	-7	N/A	-6	N/A
9/30/2013	0	-7	N/A	-7	N/A
6/30/2013	0	-6	N/A	-6	N/A

애널리스트 미래 성장 예측

수입 대 저축률: RENE 의 예상 수익 증가율이 절약률( 1.8% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: RENE 의 수익이 UK 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: RENE 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: RENE 의 수익이 UK 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: RENE 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: RENE 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

This company listing is no longer active

ReNeuron Group 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

Consensus EPS estimates upgraded to UK£0.10 loss

Consensus forecasts updated

No longer forecast to breakeven

Price target decreased to UK£2.22

Recent updates

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024

ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

New minor risk - Profitability

ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023

ReNeuron Group plc, Annual General Meeting, Aug 22, 2023

Consensus EPS estimates upgraded to UK£0.10 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023

High number of new and inexperienced directors

ReNeuron Group plc Appoints Iain Ross as Executive Chairman

Consensus forecasts updated

First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)

No longer forecast to breakeven

Less than half of directors are independent

Less than half of directors are independent

ReNeuron Group plc Appoints John Hawkins as Chief Financial Officer

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

Price target decreased to UK£2.22

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022

Price target decreased to UK£2.19

ReNeuron Group plc, Annual General Meeting, Jul 14, 2022

Price target decreased to UK£2.04

ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022

ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive Director

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Price target decreased to UK£2.04

First half 2022 earnings: EPS and revenues miss analyst expectations

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

ReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial Officer

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

New 90-day high: UK£1.11

New 90-day low: UK£0.72

First half 2021 earnings released: UK£0.22 loss per share

New 90-day low: UK£0.78

Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)

ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020

New 90-day low: UK£0.85

Analysts update estimates

ReNeuron Group plc Auditor Raises 'Going Concern' Doubt

Full year earnings released - UK£0.36 loss per share

New 90-day low - UK£1.08

New 90-day low - UK£1.22

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견